Showing 1411-1420 of 3353 results for "".
Of Sharks and Sunscreen
https://practicaldermatology.com/videos/scientifically-speaking/of-sharks-and-sunscreen/20130/Often called on to judge "Shark Tank"-style competitions, Humberto Antunes has an eye for what makes an idea work. He talks with host Joel L. Cohen, MD about ingredients for success and also offers insight on sunscreen access in the US.Get Ready for JAK Inhibitors
https://practicaldermatology.com/topics/psoriasis/get-ready-for-jak-inhibitors/19928/JAK inhibitors are going to change the way we think about refractory disease, says Brett King, MD. He addresses the significant increase in study of these agents and the many potential uses for refractory diseases like alopecia, atopic dermatitis, vitiligo, psoriasis, and more.Does Diet Matter in Management of Psoriasis?
https://practicaldermatology.com/topics/psoriasis/does-diet-matter-in-management-of-psoriasis/19653/Ronald Prussick, MD says there are dietary changes patients with psoriasis can make to potentially help manage their disease and lower their BMI, which can help improve psoriasis symptoms. He shares some tips and discusses when a referral to a registered dietician makes sense.Developing PsA: Risk Factors for Psoriasis Patients
https://practicaldermatology.com/topics/psoriasis/developing-psa-risk-factors-for-psoriasis-patients/19651/Can patients with psoriasis lessen their chance of developing psoriatic arthritis? Ronald Prussick, MD discusses the known risk factors and the importance of weight and a low BMI for these patients. He also talks about non-alcoholic fatty liver syndrome in this patient population.Topical Toxins: Now and Later
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/topical-toxins-now-and-later/18768/Topical neurotoxins are in late-stage development, with the potential to offer "softer" results and reduction of fine wrinkles. But they may not be approved for another few years. In the meantime, micro channel delivery of toxins, such as with AquaGold, is an option. Joel Schlessinger, MD, founder oASDS Updates
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/asds-updates/23823/The American Society for Dermatologic Surgery shined in Colorado for the first live annual meeting post pandemic.Advancements in Skin Protection and Skin Cancer Management
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advancements-in-skin-protection-and-skin-cancer-management/20720/Experts discuss some of the latest developments with an emphasis on implications for patient care.DermWireTV: Epsolay Approval; See My Skin from Vaseline; Jori Launch; Novartis Grant for Farmworker Justice
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-epsolay-approval-see-my-skin-from-vaseline-jori-launch-novartis-grant-for-farmworker-justice/20094/Vaseline’s new See My Skin Campaign aims to help consumers of all skin types recognize skin diseases and connect them with dermatologists who can help manage them. Uchenna Okereke, MD discusses the initiative. Farmworker Justice, an organization dedicated to empowering farmworkers to improve immigraHyperpigmentation Treatment Pearls and More
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/hyperpigmentation-treatment-pearls-and-more/20161/Corey Hartman, MD shares his approach to treating periorbital hyperpigmentation in darker skin types, including using fillers to replace volume, give lift, and replace loss of bony structures and fat pads. Dr. Hartman also discusses the benefits of Cynosure’s PicoSure device to correct hyperpigmentaDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global P